Chef: Some of that rise was due to shareholder exp
Post# of 30028
Posted On: 09/24/2014 9:27:11 AM
Chef: Some of that rise was due to shareholder expectations that we'd get the multivariant data where we'd get sens & spec numbers in the 95% range. Somehow we thought that if we did, and it was announced in Copenhagen or at the UN in front of the world....LymPro would finally get it's day in the spot light and that we'd be on our way. It turns out we didn't get the full data and the data we got was univariant instead of multivariant, so since shareholders thought they got something less than they were expecting, they were disappointed and the stock dropped.
But that is only a part of the reason the stock went up and down so fast. Money Runners is another reason. Maybe they are the main reason. They manipulated us up and down, that is why the spike and drop were so dramatic. They have since got in trouble with the law.
We started to recover some from that toward the end of August. We were trading above .125 cents expecting great things in the first couple of weeks of September, including a JV Partnership. On the Tuesday following Labor Day, shareholders learned we were getting a Master Service Agreement with ICON instead of a JV. That was a surprise to many, and the pps dropped from there. Even the revenue guidance given didn't cause the stock to go up. And of course there was the billion AS vote. That combined sent us down to the low of .083 cents.
But we've reached bottom. We closed at .096 yesterday. We are now looking forward to the LP002 "bridge data" in the next week. Even though it too will be univariant, I think shareholders are more aware now and will appreciate it more.
But the main two things we have to look forward to in the near future are:
1) Something "concrete" regarding our Partnership will be announced that Gerald said should raise shareholder value. I don't think this is a JV, but it could have something to do with the spin off. I'm speculating. But it is giving us some near term hope.
2) The MANF Orphan indication data to be presented in Boston on Oct. 6th. This ocular indication will be in addition to our Retinitis orphan candidate.
I think we slowly gain momentum going into December when the validation study is completed by ICON and we get that multivariant data and start commercialization. We'll also be getting back FDA approval of our MANF orphans by end of December or Q1 2015. And of course, we'll begin our Eltoprazine phase 2b trial in Q1 2015.
I think we'll be above .20 cents in January and they'll announce up listing. If we up list in February at .30 cents, we'll have a 1:15 or so Reverse Split, and we'll be off and running. After the up listing, LymPro revenue will be nothing but a positive force on the pps. We'll do well.
I think this is a very reasonable scenario of how things could go. Nothing guaranteed of course.
But that is only a part of the reason the stock went up and down so fast. Money Runners is another reason. Maybe they are the main reason. They manipulated us up and down, that is why the spike and drop were so dramatic. They have since got in trouble with the law.
We started to recover some from that toward the end of August. We were trading above .125 cents expecting great things in the first couple of weeks of September, including a JV Partnership. On the Tuesday following Labor Day, shareholders learned we were getting a Master Service Agreement with ICON instead of a JV. That was a surprise to many, and the pps dropped from there. Even the revenue guidance given didn't cause the stock to go up. And of course there was the billion AS vote. That combined sent us down to the low of .083 cents.
But we've reached bottom. We closed at .096 yesterday. We are now looking forward to the LP002 "bridge data" in the next week. Even though it too will be univariant, I think shareholders are more aware now and will appreciate it more.
But the main two things we have to look forward to in the near future are:
1) Something "concrete" regarding our Partnership will be announced that Gerald said should raise shareholder value. I don't think this is a JV, but it could have something to do with the spin off. I'm speculating. But it is giving us some near term hope.
2) The MANF Orphan indication data to be presented in Boston on Oct. 6th. This ocular indication will be in addition to our Retinitis orphan candidate.
I think we slowly gain momentum going into December when the validation study is completed by ICON and we get that multivariant data and start commercialization. We'll also be getting back FDA approval of our MANF orphans by end of December or Q1 2015. And of course, we'll begin our Eltoprazine phase 2b trial in Q1 2015.
I think we'll be above .20 cents in January and they'll announce up listing. If we up list in February at .30 cents, we'll have a 1:15 or so Reverse Split, and we'll be off and running. After the up listing, LymPro revenue will be nothing but a positive force on the pps. We'll do well.
I think this is a very reasonable scenario of how things could go. Nothing guaranteed of course.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼